7 March 2023 - If approved, remestemcel-L will be the first allogeneic “off the shelf” cellular medicine in the US and ...
13 February 2023 - A top official from the US FDA said he wants to see something similar to the agency’s ...
12 February 2023 - IASO Biotherapeutics today announced that the US FDA has granted both regenerative medicine advanced therapy designation ...
9 February 2023 - Mesoblast today announced that the US FDA's Office of Tissues and Advanced Therapies has granted regenerative ...
31 January 2023 - Granted fast track designation by US FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell ...
26 January 2023 - DiscGenics today announced the US FDA granted regenerative medicine advanced therapy designation to injectable disc cell ...
23 December 2022 - Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumour. ...
19 December 2022 - Pierre Fabre to lead commercialisation and distribution activities in Europe. ...
6 December 2022 - Stable disease observed in two out of four evaluable patients in eAPC Phase 1/2 trial including a ...
29 November 2022 - CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout. ...
4 November 2022 - The US FDA laid out its recommendations for sponsors to study multiple versions of a cellular or ...
27 October 2022 - MT-101 is the first mRNA engineered CAR monocyte therapy to be dosed in humans. ...
17 October 2022 - First treatment in 30 years to improve upon standard care for second-line treatment of DLBCL. ...
14 October 2022 - Ebvallo on track to be the first ever allogeneic T-cell therapy approved. ...
29 September 2022 - EMA is launching a pilot to support the translation of basic research developments into medicines that could ...